IL96229A - The use of an interferon-gamma polypeptide for the preparation of medicinal preparations for the treatment of primary malignant tumors of the maple in the Edri facial pathway - Google Patents

The use of an interferon-gamma polypeptide for the preparation of medicinal preparations for the treatment of primary malignant tumors of the maple in the Edri facial pathway

Info

Publication number
IL96229A
IL96229A IL96229A IL9622990A IL96229A IL 96229 A IL96229 A IL 96229A IL 96229 A IL96229 A IL 96229A IL 9622990 A IL9622990 A IL 9622990A IL 96229 A IL96229 A IL 96229A
Authority
IL
Israel
Prior art keywords
gamma interferon
treatment
activity
pleura
polypeptide
Prior art date
Application number
IL96229A
Other languages
English (en)
Hebrew (he)
Other versions
IL96229A0 (en
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of IL96229A0 publication Critical patent/IL96229A0/xx
Publication of IL96229A publication Critical patent/IL96229A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL96229A 1989-11-10 1990-11-02 The use of an interferon-gamma polypeptide for the preparation of medicinal preparations for the treatment of primary malignant tumors of the maple in the Edri facial pathway IL96229A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR898914780A FR2654343B1 (fr) 1989-11-10 1989-11-10 Utilisation d'un polypeptide ayant l'activite de l'interferon gamma pour la preparation de compositions pharmaceutiques destinees au traitement de cancers primitifs de la plevre.

Publications (2)

Publication Number Publication Date
IL96229A0 IL96229A0 (en) 1991-08-16
IL96229A true IL96229A (en) 1998-04-05

Family

ID=9387288

Family Applications (1)

Application Number Title Priority Date Filing Date
IL96229A IL96229A (en) 1989-11-10 1990-11-02 The use of an interferon-gamma polypeptide for the preparation of medicinal preparations for the treatment of primary malignant tumors of the maple in the Edri facial pathway

Country Status (14)

Country Link
US (1) US5108743A (de)
EP (1) EP0427633B1 (de)
JP (1) JPH07103042B2 (de)
KR (1) KR0169975B1 (de)
AT (1) ATE96035T1 (de)
AU (1) AU645042B2 (de)
CA (1) CA2029670A1 (de)
DE (1) DE69004051T2 (de)
DK (1) DK0427633T3 (de)
FR (1) FR2654343B1 (de)
HU (1) HU206049B (de)
IL (1) IL96229A (de)
OA (1) OA09469A (de)
ZA (1) ZA907649B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2148988C1 (ru) * 1997-07-21 2000-05-20 Самойленко Игорь Иннокентьевич Усовершенствованная лекарственная форма человеческого интерферона-свеча
JP5043294B2 (ja) * 2003-09-29 2012-10-10 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 中皮腫を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0219073B1 (de) * 1985-10-15 1990-03-07 F. Hoffmann-La Roche Ag Stabilisierung von Interferonen
WO1987005518A1 (en) * 1986-03-17 1987-09-24 Schering Corporation Treatment of cancers with gamma interferon
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
EP0278715A3 (de) * 1987-02-09 1989-03-08 Schering Corporation Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen

Also Published As

Publication number Publication date
KR910009280A (ko) 1991-06-28
AU645042B2 (en) 1994-01-06
JPH07103042B2 (ja) 1995-11-08
EP0427633A1 (de) 1991-05-15
US5108743A (en) 1992-04-28
DE69004051D1 (de) 1993-11-25
EP0427633B1 (de) 1993-10-20
CA2029670A1 (fr) 1991-05-11
ZA907649B (en) 1991-11-27
DK0427633T3 (da) 1994-01-31
JPH03188025A (ja) 1991-08-16
HUT55995A (en) 1991-07-29
AU6651190A (en) 1991-05-16
DE69004051T2 (de) 1994-03-03
OA09469A (fr) 1992-11-15
IL96229A0 (en) 1991-08-16
FR2654343A1 (fr) 1991-05-17
ATE96035T1 (de) 1993-11-15
HU206049B (en) 1992-08-28
KR0169975B1 (ko) 1999-02-01
FR2654343B1 (fr) 1994-08-05
HU907180D0 (en) 1991-05-28

Similar Documents

Publication Publication Date Title
RU94028670A (ru) Иммунопотенциирующие агенты, способы лечения иммунодефицитных млекопитающих, а также вирусных инфекций и рака у млекопитающих
MY117892A (en) Therapeutic compounds
HU206987B (en) Process for producing oral pharmaceutical compositions comprising alpha- or beta-interferon, suitable for reducing side effects of cancer therapy
Heptinstall et al. Peripheral neuritis in systemic lupus erythematosus
EP0980254A1 (de) Antivirale pharmazeutische zusammensetzungen welche glycyrrhizinsäure und mindestens ein protein mit antiviraler wirksamkeit enthalten
Sabroe et al. Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin.
JPH03501382A (ja) 組換えコロニー刺激因子‐１の使用
NL8501995A (nl) Werkwijze voor het remmen van acuut stralingssyndroom en het optreden van septiceem en daarvoor te gebruiken preparaat.
EP0396903B1 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL
IL96229A (en) The use of an interferon-gamma polypeptide for the preparation of medicinal preparations for the treatment of primary malignant tumors of the maple in the Edri facial pathway
US5268169A (en) Treatment method of ovarian cancer using interferon gamma
JPS6236331A (ja) 抗感染症剤ならびに免疫賦活剤
Christophersen et al. Interferon therapy in neoplastic disease: a preliminary report
JP2002275089A (ja) 組み換えコロニー刺激因子−１の使用
WO1998004280A2 (en) Topical composition containing amino acid in combination with either interferon or thymidine derivatives for treating viral or inflammation diseases
Werenne et al. Antiviral effect of bacterially produced human interferon (Hu-IFNα2) against experimental vaccinia infection in calves
US5780012A (en) Method for reducing lung afflictions by inhalation of cytokine solutions
AU706703B2 (en) 1,3-dicarboxylic germanium complex and its therapeutic use
US5358709A (en) Antitumoral composition based on polypeptides having human interleukin 2 activity
AU632528B2 (en) Use of certain gamma interferons in the preparation of pharmaceutical compositions intended for the treatment of cancer of the ovary by intra-peritoneal route
JPH07503705A (ja) 医薬的リジン含有ポリペプチド組成物およびその使用法
JPH0331215A (ja) 制癌療法支持剤
US6143742A (en) Treatment for necrotizing infections
JP3481954B2 (ja) 気胸治療のための医薬組成物の製造のためのヒトインターロイキン２の活性を有するポリペプチドの利用
JPH059131A (ja) 抗癌剤

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HCE Change of name and address of proprietor(s)
KB Patent renewed
HCA Change of name of proprietor(s) after amalgamation
KB Patent renewed
FF Patent granted
EXP Patent expired